Table 2 Hepcidin and risk of RBC transfusion with IV iron therapy
Variable | IV iron | Placebo | Risk ratio (95% CI) | p value |
|---|---|---|---|---|
Hepcidin ≤ 53.0 μg/L | ||||
Number RBC units/patients | 38/44 | 80/44 | ||
Median RBC units (IQR) | 1 (0–2) | 1 (0–3) | 0.48 (0.26–0.85) | 0.013 |
Hepcidin 1st tertile (0–20.1 μg/L) | ||||
Number RBC units/number patients | 23/22 | 35/21 | ||
Median RBC units (IQR) | 1 (0–2) | 0 (0–2) | 0.63 (0.26–1.50) | 0.293 |
Hepcidin 2nd tertile (20.1–53.0 μg/L) | ||||
Number RBC units/number patients | 15/22 | 45/23 | ||
Median RBC units (IQR) | 0 (0–1) | 1 (0–3) | 0.35 (0.16–0.77) | 0.009 |
Hepcidin 3rd tertile (> 53.0 μg/L) | ||||
Number RBC units/number patients | 43/22 | 34/23 | ||
Median RBC units (IQR) | 1 (0–3) | 1 (0–3) | 1.33 (0.57–3.08) | 0.518 |